PT1345607E - Combinação terapêutica de amlodipina e benazepril/benazeprilato - Google Patents
Combinação terapêutica de amlodipina e benazepril/benazeprilato Download PDFInfo
- Publication number
- PT1345607E PT1345607E PT01992150T PT01992150T PT1345607E PT 1345607 E PT1345607 E PT 1345607E PT 01992150 T PT01992150 T PT 01992150T PT 01992150 T PT01992150 T PT 01992150T PT 1345607 E PT1345607 E PT 1345607E
- Authority
- PT
- Portugal
- Prior art keywords
- amlodipine
- benazepril
- pharmaceutically acceptable
- acceptable salt
- amount
- Prior art date
Links
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 title claims abstract description 91
- 229960000528 amlodipine Drugs 0.000 title claims abstract description 86
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 title claims abstract description 82
- 229960004530 benazepril Drugs 0.000 title claims abstract description 74
- MADRIHWFJGRSBP-ROUUACIJSA-N benazeprilat Chemical compound C([C@H](N[C@H]1CCC2=CC=CC=C2N(C1=O)CC(=O)O)C(O)=O)CC1=CC=CC=C1 MADRIHWFJGRSBP-ROUUACIJSA-N 0.000 title claims abstract description 16
- 229960004067 benazeprilat Drugs 0.000 title claims abstract description 15
- 230000001225 therapeutic effect Effects 0.000 title description 3
- 150000003839 salts Chemical class 0.000 claims abstract description 48
- VPSRQEHTHIMDQM-FKLPMGAJSA-N benazepril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 VPSRQEHTHIMDQM-FKLPMGAJSA-N 0.000 claims abstract description 22
- 229960003619 benazepril hydrochloride Drugs 0.000 claims abstract description 22
- 206010020772 Hypertension Diseases 0.000 claims abstract description 16
- 238000011282 treatment Methods 0.000 claims abstract description 14
- 239000012458 free base Substances 0.000 claims abstract description 11
- 230000036772 blood pressure Effects 0.000 claims abstract description 8
- 239000005541 ACE inhibitor Substances 0.000 claims abstract description 7
- 206010002383 Angina Pectoris Diseases 0.000 claims abstract description 7
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 7
- 208000002815 pulmonary hypertension Diseases 0.000 claims abstract description 6
- 208000019693 Lung disease Diseases 0.000 claims abstract description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 5
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims abstract description 4
- 206010019233 Headaches Diseases 0.000 claims abstract description 4
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims abstract description 4
- 208000021642 Muscular disease Diseases 0.000 claims abstract description 4
- 201000009623 Myopathy Diseases 0.000 claims abstract description 4
- 208000018262 Peripheral vascular disease Diseases 0.000 claims abstract description 4
- 208000001647 Renal Insufficiency Diseases 0.000 claims abstract description 4
- 208000006011 Stroke Diseases 0.000 claims abstract description 4
- 230000000747 cardiac effect Effects 0.000 claims abstract description 4
- 208000010877 cognitive disease Diseases 0.000 claims abstract description 4
- 208000033679 diabetic kidney disease Diseases 0.000 claims abstract description 4
- 231100000869 headache Toxicity 0.000 claims abstract description 4
- 201000006370 kidney failure Diseases 0.000 claims abstract description 4
- 208000010125 myocardial infarction Diseases 0.000 claims abstract description 4
- 230000002265 prevention Effects 0.000 claims abstract description 4
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 18
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical group OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 claims description 12
- 229960004005 amlodipine besylate Drugs 0.000 claims description 12
- 239000002552 dosage form Substances 0.000 claims description 12
- 238000009472 formulation Methods 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 9
- 239000002585 base Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 7
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 abstract description 8
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 239000003826 tablet Substances 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 229940127291 Calcium channel antagonist Drugs 0.000 description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 7
- 235000019359 magnesium stearate Nutrition 0.000 description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 7
- 239000008108 microcrystalline cellulose Substances 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 230000035488 systolic blood pressure Effects 0.000 description 6
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 229960000913 crospovidone Drugs 0.000 description 5
- 230000035487 diastolic blood pressure Effects 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 229940080288 lotrel Drugs 0.000 description 5
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 5
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 4
- 229920000881 Modified starch Polymers 0.000 description 4
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 235000019700 dicalcium phosphate Nutrition 0.000 description 4
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229940068968 polysorbate 80 Drugs 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 238000009097 single-agent therapy Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 206010030124 Oedema peripheral Diseases 0.000 description 3
- 230000003276 anti-hypertensive effect Effects 0.000 description 3
- 239000000480 calcium channel blocker Substances 0.000 description 3
- 229910052681 coesite Inorganic materials 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 229910052906 cristobalite Inorganic materials 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229920003109 sodium starch glycolate Polymers 0.000 description 3
- 229940079832 sodium starch glycolate Drugs 0.000 description 3
- 239000008109 sodium starch glycolate Substances 0.000 description 3
- 229910052682 stishovite Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229910052905 tridymite Inorganic materials 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- 208000007530 Essential hypertension Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical class [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 229960001021 lactose monohydrate Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- QQUGAJMOSWOMFG-UHFFFAOYSA-N 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylic acid Chemical group OC(=O)C1=C(COCCN)NC(C)=C(C(O)=O)C1C1=CC=CC=C1Cl QQUGAJMOSWOMFG-UHFFFAOYSA-N 0.000 description 1
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 1
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000000924 Right ventricular hypertrophy Diseases 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010047295 Ventricular hypertrophy Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- SJSNKICFTZWKLT-KEHAGZLWSA-N benzenesulfonic acid;2-[(3s)-3-[[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-2-oxo-4,5-dihydro-3h-1-benzazepin-1-yl]acetic acid;3-o-ethyl 5-o-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate;hydrochloride Chemical compound Cl.OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl.C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 SJSNKICFTZWKLT-KEHAGZLWSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 229940031705 hydroxypropyl methylcellulose 2910 Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007942 layered tablet Substances 0.000 description 1
- 229940080268 lotensin Drugs 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229940036132 norvasc Drugs 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 208000037905 systemic hypertension Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2000/034246 WO2002049645A1 (en) | 2000-12-18 | 2000-12-18 | Therapeutic combination of amlodipine and benazepril |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1345607E true PT1345607E (pt) | 2007-01-31 |
Family
ID=21742073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT01992150T PT1345607E (pt) | 2000-12-18 | 2001-12-17 | Combinação terapêutica de amlodipina e benazepril/benazeprilato |
Country Status (26)
| Country | Link |
|---|---|
| EP (3) | EP1365761A1 (enExample) |
| JP (3) | JP2004516266A (enExample) |
| KR (3) | KR20040007420A (enExample) |
| CN (2) | CN1461218A (enExample) |
| AT (1) | ATE338549T1 (enExample) |
| AU (4) | AU2581601A (enExample) |
| BR (2) | BR0017386A (enExample) |
| CA (2) | CA2432638A1 (enExample) |
| CY (1) | CY1106275T1 (enExample) |
| CZ (2) | CZ20031678A3 (enExample) |
| DE (1) | DE60122928T2 (enExample) |
| DK (1) | DK1345607T3 (enExample) |
| EC (1) | ECSP034658A (enExample) |
| ES (1) | ES2272565T3 (enExample) |
| HU (2) | HUP0302455A3 (enExample) |
| IL (4) | IL156136A0 (enExample) |
| MX (2) | MXPA03005462A (enExample) |
| NO (2) | NO20032765L (enExample) |
| NZ (1) | NZ526467A (enExample) |
| PL (2) | PL362252A1 (enExample) |
| PT (1) | PT1345607E (enExample) |
| RU (1) | RU2292206C2 (enExample) |
| SI (1) | SI1345607T1 (enExample) |
| SK (2) | SK7652003A3 (enExample) |
| WO (2) | WO2002049645A1 (enExample) |
| ZA (1) | ZA200304514B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0214383A (pt) * | 2001-11-23 | 2004-11-03 | Solvay Pharm Gmbh | Tratamento de hipertonia durante a fase aguda do ataque de apoplexia |
| US20040229901A1 (en) * | 2003-02-24 | 2004-11-18 | Lauren Otsuki | Method of treatment of disease using an adenosine A1 receptor antagonist |
| AR044069A1 (es) | 2003-04-25 | 2005-08-24 | Nova Cardia Inc | Un metodo de diuresis mejorada en individuos con funcion renal deteriorada |
| AU2004281541B2 (en) * | 2003-10-20 | 2008-05-01 | Novartis Ag | Tbenazpril and amlodipine for reducing cardiovascular morbidity |
| WO2005074927A1 (en) * | 2004-02-09 | 2005-08-18 | Novartis Ag | Therapeutic combination of amlodipine and benazepril/ benazeprilat for the treatment of hypertension |
| WO2005079772A2 (en) * | 2004-02-18 | 2005-09-01 | Sepracor Inc. | Combination of (s)-amlodipine and an ace inhibitor, and methods for reducing hypertension |
| DE102004011512B4 (de) | 2004-03-08 | 2022-01-13 | Boehringer Ingelheim Vetmedica Gmbh | Pharmazeutische Zubereitung enthaltend Pimobendan |
| US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
| EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
| US20080268049A1 (en) * | 2005-02-11 | 2008-10-30 | Dhaliwal Mona | Stable Solid Dosage Forms of Amlodipine and Benazepril |
| WO2006092732A2 (en) * | 2005-03-04 | 2006-09-08 | Aurobindo Pharma Ltd | Stable solid dosage form of antihypertensive agent |
| MX2007011119A (es) | 2005-03-15 | 2007-11-14 | Lupin Ltd | Composiciones farmaceuticas de amlodipino y benazepril. |
| ES2303198T3 (es) * | 2005-09-28 | 2008-08-01 | Teva Pharmaceutical Industries Ltd. | Combinaciones estables de besilato de amlodipina e hidrocloruro de benazeprilo. |
| AU2005336956A1 (en) * | 2005-09-28 | 2007-04-12 | Teva Pharmaceutical Industries Ltd. | Stable combinations of amlodipine besylate and benazepril hydrochloride |
| US8158146B2 (en) | 2005-09-28 | 2012-04-17 | Teva Pharmaceutical Industries Ltd. | Stable combinations of amlodipine besylate and benazepril hydrochloride |
| EP1920785A1 (en) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
| IT1398168B1 (it) * | 2010-02-16 | 2013-02-14 | Chiesi Farma Spa | Uso di ingredienti attivi in combinazione per il trattamento delle complicanze del diabete. |
| WO2011161223A2 (en) | 2010-06-23 | 2011-12-29 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts |
| CN102389431A (zh) * | 2011-09-28 | 2012-03-28 | 济南龙华医药技术有限公司 | 一种含有盐酸贝尼地平和盐酸贝那普利的复方制剂及其应用 |
| RS54475B1 (sr) | 2011-12-21 | 2016-06-30 | Novartis Tiergesundheit Ag | Nova kombinacija |
| ES2924478T3 (es) | 2012-03-15 | 2022-10-07 | Boehringer Ingelheim Vetmedica Gmbh | Formulación de comprimidos farmacéuticos para el sector médico veterinario, método de producción y uso de los mismos |
| US20150218103A1 (en) * | 2012-08-25 | 2015-08-06 | The Johns Hopkins University | Gapdh cascade inhibitor compounds and methods of use and treatment of stress induced disorders including mental illness |
| JP6272475B2 (ja) | 2013-07-19 | 2018-01-31 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ | 防腐エーテル化シクロデキストリン誘導体含有液体水性医薬組成物 |
| CN110721164B (zh) | 2013-12-04 | 2024-09-17 | 勃林格殷格翰动物保健有限公司 | 匹莫苯的改善的药物组合物 |
| CN108778334A (zh) * | 2016-03-24 | 2018-11-09 | 第三共株式会社 | 用于治疗肾脏疾病的药物 |
| US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
| CN110290791A (zh) | 2016-11-16 | 2019-09-27 | 灵北拉荷亚研究中心公司 | 药物制剂 |
| ES2966939T3 (es) | 2016-11-16 | 2024-04-25 | H Lundbeck As | Una forma cristalina de un inhibidor de MAGL |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6162802A (en) * | 1992-03-10 | 2000-12-19 | Papa; Joseph | Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor |
| MX9706957A (es) * | 1995-03-16 | 1997-11-29 | Pfizer | Composicion que contiene amlodipina, o una sal, o felodipina y un inhibidor de enzima convertidora de angiotensina. |
| KR19980703647A (ko) * | 1995-04-07 | 1998-12-05 | 베르너발데크 | 베나제프릴 또는 베나제프릴라트 및 발사르탄을 함유하는조성물 |
| EP0795327A1 (en) * | 1996-03-13 | 1997-09-17 | Pfizer Inc. | Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin |
-
2000
- 2000-12-18 WO PCT/US2000/034246 patent/WO2002049645A1/en not_active Ceased
- 2000-12-18 CA CA002432638A patent/CA2432638A1/en not_active Abandoned
- 2000-12-18 JP JP2002550985A patent/JP2004516266A/ja active Pending
- 2000-12-18 HU HU0302455A patent/HUP0302455A3/hu unknown
- 2000-12-18 MX MXPA03005462A patent/MXPA03005462A/es not_active Application Discontinuation
- 2000-12-18 AU AU2581601A patent/AU2581601A/xx active Pending
- 2000-12-18 CN CN00820080A patent/CN1461218A/zh active Pending
- 2000-12-18 BR BR0017386-0A patent/BR0017386A/pt not_active Application Discontinuation
- 2000-12-18 KR KR10-2003-7007578A patent/KR20040007420A/ko not_active Withdrawn
- 2000-12-18 CZ CZ20031678A patent/CZ20031678A3/cs unknown
- 2000-12-18 AU AU2001225816A patent/AU2001225816B2/en not_active Ceased
- 2000-12-18 EP EP00989288A patent/EP1365761A1/en not_active Withdrawn
- 2000-12-18 IL IL15613600A patent/IL156136A0/xx unknown
- 2000-12-18 PL PL00362252A patent/PL362252A1/xx not_active Application Discontinuation
- 2000-12-18 SK SK765-2003A patent/SK7652003A3/sk not_active Application Discontinuation
-
2001
- 2001-12-17 PL PL01360989A patent/PL360989A1/xx not_active Application Discontinuation
- 2001-12-17 JP JP2002550986A patent/JP2004519440A/ja not_active Withdrawn
- 2001-12-17 ES ES01992150T patent/ES2272565T3/es not_active Expired - Lifetime
- 2001-12-17 AU AU2002232620A patent/AU2002232620B9/en not_active Ceased
- 2001-12-17 DK DK01992150T patent/DK1345607T3/da active
- 2001-12-17 DE DE60122928T patent/DE60122928T2/de not_active Revoked
- 2001-12-17 AT AT01992150T patent/ATE338549T1/de active
- 2001-12-17 CZ CZ20031677A patent/CZ301424B6/cs not_active IP Right Cessation
- 2001-12-17 KR KR1020097004242A patent/KR20090033914A/ko not_active Ceased
- 2001-12-17 CA CA002432282A patent/CA2432282A1/en not_active Abandoned
- 2001-12-17 HU HU0302456A patent/HUP0302456A3/hu unknown
- 2001-12-17 IL IL15626701A patent/IL156267A0/xx unknown
- 2001-12-17 MX MXPA03005463A patent/MXPA03005463A/es active IP Right Grant
- 2001-12-17 BR BR0116228-4A patent/BR0116228A/pt not_active IP Right Cessation
- 2001-12-17 SK SK764-2003A patent/SK7642003A3/sk not_active Application Discontinuation
- 2001-12-17 EP EP01992150A patent/EP1345607B1/en not_active Revoked
- 2001-12-17 RU RU2003121019/15A patent/RU2292206C2/ru not_active IP Right Cessation
- 2001-12-17 KR KR10-2003-7007754A patent/KR20030061840A/ko not_active Ceased
- 2001-12-17 EP EP06003150A patent/EP1674099A1/en not_active Withdrawn
- 2001-12-17 AU AU3262002A patent/AU3262002A/xx active Pending
- 2001-12-17 CN CNA018208398A patent/CN1481241A/zh active Pending
- 2001-12-17 NZ NZ526467A patent/NZ526467A/en unknown
- 2001-12-17 WO PCT/US2001/048808 patent/WO2002049646A1/en not_active Ceased
- 2001-12-17 PT PT01992150T patent/PT1345607E/pt unknown
- 2001-12-17 SI SI200130662T patent/SI1345607T1/sl unknown
-
2003
- 2003-06-10 ZA ZA200304514A patent/ZA200304514B/xx unknown
- 2003-06-17 NO NO20032765A patent/NO20032765L/no not_active Application Discontinuation
- 2003-06-17 NO NO20032766A patent/NO20032766L/no not_active Application Discontinuation
- 2003-06-17 EC EC2003004658A patent/ECSP034658A/es unknown
-
2006
- 2006-11-30 CY CY20061101728T patent/CY1106275T1/el unknown
-
2008
- 2008-04-10 IL IL190802A patent/IL190802A0/en unknown
- 2008-04-10 IL IL190801A patent/IL190801A0/en unknown
-
2009
- 2009-10-09 JP JP2009235225A patent/JP2010043111A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1345607E (pt) | Combinação terapêutica de amlodipina e benazepril/benazeprilato | |
| CZ117396A3 (en) | Novel pharmaceutical composition containing ace inhibitor ramipril and dyhydropyridine compound | |
| ES2435240T3 (es) | Composiciones de dosis fija farmacéuticas sólidas que comprenden irbesartán y amlodipina, su preparación y su aplicación terapéutica | |
| US6162802A (en) | Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor | |
| KR20110107877A (ko) | 유기 화합물의 조합제제 | |
| NZ575422A (en) | Solid dosage form of olmesartan medoxomil and amlodipine with reduced amounts of impurities and reducing sugars | |
| EA015122B1 (ru) | Фармацевтическая композиция и ее применение для лечения тромбоза | |
| CZ138198A3 (cs) | Spojení fixní dávky inhibitoru angiotensin konvertujícího enzymu a antagonisty vápníkového kanálu, způsob pro jejich přípravu a použití v léčbě kardiovaskulárních onemocnění | |
| US20080287412A1 (en) | Therapeutic combination of amlodipine and benazepril/benazeprilat | |
| US20040048905A1 (en) | Therapeutic combination of amlodipine and benazepril | |
| HK1094147A (en) | Therapeutic combination of amlodipine and benazepril/benazeprilat | |
| HK1059566B (en) | Therapeutic combination of amlodipine and benazepril/benazeprilat | |
| ZA200304330B (en) | Therapeutic combination of amlodipine and benazepril. | |
| NZ526385A (en) | High dose therapeutic combination of amlodipine and benazepril | |
| KR102066832B1 (ko) | 텔미사르탄 또는 그의 약제학적으로 허용가능한 염을 포함하는 인습성 및 용출률이 향상된 제제 |